Cubist Systematic Strategies LLC Makes New Investment in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Cubist Systematic Strategies LLC acquired a new stake in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 32,031 shares of the company’s stock, valued at approximately $37,000.

Separately, Ground Swell Capital LLC bought a new position in Protalix BioTherapeutics during the second quarter valued at approximately $73,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Price Performance

NYSE:PLX opened at $1.01 on Wednesday. The company has a market cap of $74.05 million, a price-to-earnings ratio of 25.25 and a beta of 0.70. Protalix BioTherapeutics, Inc. has a 1 year low of $0.82 and a 1 year high of $1.90. The stock’s 50 day simple moving average is $1.02 and its two-hundred day simple moving average is $1.12.

Protalix BioTherapeutics (NYSE:PLX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.05). Protalix BioTherapeutics had a negative return on equity of 45.15% and a negative net margin of 38.62%. The business had revenue of $13.47 million during the quarter, compared to the consensus estimate of $12.50 million. During the same quarter in the prior year, the firm posted ($0.07) EPS. As a group, analysts anticipate that Protalix BioTherapeutics, Inc. will post 0.06 EPS for the current year.

Protalix BioTherapeutics Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.